In a patient with dementia who is aggressive and agitated and is already receiving lorazepam gel, what additional medication can be given to help calm her?

Add an Atypical Antipsychotic to the Lorazepam

For a patient with dementia who is aggressive and agitated despite lorazepam gel, add a low-dose atypical antipsychotic—specifically risperidone 0.25 mg at bedtime or quetiapine 12.5 mg twice daily—as these have the strongest guideline support for controlling severe psychomotor agitation and combativeness in dementia. 1

Why Antipsychotics Are Indicated

Your patient has already been started on lorazepam, but benzodiazepines alone have significant limitations in dementia-related agitation:

• Benzodiazepines can paradoxically worsen agitation in approximately 10% of dementia patients 1
• Regular benzodiazepine use leads to tolerance, cognitive impairment, and increased fall risk 1, 2
• The FDA label explicitly warns that lorazepam may worsen confusion and is not recommended for primary use in dementia 2
• Most critically: A 2025 geriatric emergency guidelines review found benzodiazepines, particularly midazolam, had the worst safety profile of any medication for agitation in older adults, with high rates of serious adverse events 3

The evidence strongly supports adding an antipsychotic rather than increasing benzodiazepine dosing.

Specific Medication Recommendations

First-Line: Atypical Antipsychotics

Risperidone (Risperdal):

• Start 0.25 mg at bedtime
• Maximum 2-3 mg/day in divided doses
• Current research supports low dosages
• Extrapyramidal symptoms may occur at ≥2 mg/day 1

Quetiapine (Seroquel):

• Start 12.5 mg twice daily
• Maximum 200 mg twice daily
• More sedating, which may be beneficial
• Beware of transient orthostatic hypotension 1
• A 2025 geriatric study found oral quetiapine has a favorable safety profile 3

Olanzapine (Zyprexa):

• Start 2.5 mg at bedtime
• Maximum 10 mg/day in divided doses
• Generally well tolerated 1
• A 2002 RCT showed IM olanzapine superior to lorazepam at 24 hours for sustained agitation control in dementia 4

Alternative: Mood Stabilizers (If Antipsychotics Fail or Are Contraindicated)

Trazodone (Desyrel):

• Start 25 mg/day
• Maximum 200-400 mg/day in divided doses
• Useful alternative for severe agitated, repetitive, and combative behaviors
• Use with caution if premature ventricular contractions present 1

Critical Safety Considerations

Black Box Warnings You Must Discuss

Before prescribing any antipsychotic, you must:

1. Document the risk-benefit discussion with the patient (if feasible) and surrogate decision maker 5
2. Explain that antipsychotics increase mortality risk in elderly dementia patients
3. Discuss cerebrovascular event risks, particularly with risperidone
4. Only use when symptoms are severe, dangerous, or cause significant distress 5

Avoid These Dangerous Combinations

• Do NOT combine parenteral benzodiazepines with antipsychotics in older adults—this dramatically increases adverse events 3
• Do NOT use typical antipsychotics (haloperidol, etc.) as first-line; they carry 50% risk of tardive dyskinesia after 2 years in elderly patients 1
• Do NOT continue lorazepam long-term—it causes tolerance, addiction, and cognitive impairment 1, 2

Treatment Algorithm

Step 1: Start risperidone 0.25 mg at bedtime OR quetiapine 12.5 mg twice daily while continuing current lorazepam dose

Step 2: Titrate antipsychotic upward every 5-7 days to minimum effective dose as tolerated 1

Step 3: Once agitation controlled, begin tapering lorazepam to avoid long-term benzodiazepine complications 1

Step 4: Reassess with quantitative measure at 4 weeks 5

• If no response: taper and discontinue antipsychotic 5
• If response: continue at lowest effective dose, but plan for eventual taper trial 5

Step 5: After 9 months of stability, attempt dose reduction to reassess need 1

Common Pitfalls to Avoid

1. Using haloperidol as first-line: While effective, typical antipsychotics have significantly worse extrapyramidal and tardive dyskinesia risks in elderly patients 1

2. Continuing benzodiazepines indefinitely: The guidelines explicitly state benzodiazepines should be infrequent, low-dose, short-acting agents used for brief periods only 1

3. Not addressing reversible causes: Before escalating medications, ensure you've ruled out pain, constipation, urinary retention, infection, and medication side effects 6

4. Using parenteral routes unnecessarily: Oral formulations have significantly lower adverse event rates than IM or IV in older adults 3

5. Failing to document informed consent: The 2016 APA guidelines mandate documented discussion of risks/benefits before initiating antipsychotics 5

Monitoring Requirements

• Baseline: ECG (QTc interval), CBC, liver enzymes, renal function
• Ongoing: Monitor for extrapyramidal symptoms, sedation, orthostasis, falls
• Regular reassessment: Use quantitative agitation scales to track response 5
• Long-term: If on carbamazepine or valproate, monitor CBC and liver enzymes regularly 1

The evidence clearly supports adding a low-dose atypical antipsychotic to your current regimen rather than increasing benzodiazepines, which pose unacceptable risks in this population.